CAPR CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Capricor Therapeutics, Inc.

CAPR CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Capricor Therapeutics, Inc.Glancy Prongay Wolke & Rotter LLP (“GPWR”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.IF YOU SUFFERED A LOSS ON YOUR CAPRICOR INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.What Happened?On July 27, 2026, before the market opened, the U.S. Food and Drug Administration (“FDA”) released briefing documents ahead of its July 29 advisory committee (“AdCom”) meeting for the BLA. According to the briefing documents, Capricor made changes to the pre-specified statistical analysis plan (“SAP”) and the final version "was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon." Critically, the final SAP was created one day before the data was unblinded. The FDA disagreed with the changes made to the SAP, stating that the "FDA does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified, as it adds complexity and reduces accuracy." As a result, the FDA stated that it “considers [Capricor’s] analyses based on the post-study SAP versions to be post-hoc and exploratory.” According to the briefing documents, "the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness."On this news, Capricor’s stock fell $12.70, or 64%, to close at $7.00 per share on July 27, 2026, on unusually heavy trading volume.On July 29, 2026, the AdCom met to discuss the Deramiocel BLA. The next day, Medscape reported that the panel relied on SAP version 1.1 as the “prespecified plan” and, in a non-binding 9-3 vote, the panel “concluded that the available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy.”On this news, Capricor’s stock fell $2.38, or 36%, to close at $4.19 per share on July 30, 2026, on unusually heavy trading volume.What Is The Lawsuit About?The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel; (2) that the FDA had not agreed to those changes before the Company resubmitted the Deramiocel BLA; (3) that, as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) that, as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.If you purchased or otherwise acquired Capricor securities during the Class Period, you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff.Contact Us to Participate or Learn More:If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:Charles Linehan, Esq.Glancy Prongay Wolke & Rotter LLP1925 Century Park East, Suite 2100Los Angeles, California 90067Telephone: 310-201-9150Toll-Free: 888-773-9224Visit our website at www.glancylaw.com.Email: shareholders@glancylaw.comFollow us for updates on LinkedIn, Twitter, or Facebook.If you inquire by email, please include your mailing address, telephone number and number of shares purchased.To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Glancy Prongay Wolke & Rotter LLP1925 Century Park East, Suite 2100Los Angeles, CA 90067Charles LinehanEmail: shareholders@glancylaw.comTelephone: 310-201-9150Toll-Free: 888-773-9224Visit our website at: www.glancylaw.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20260730561371/en/

Raccontata damorningstar.combenzinga.com